Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy IDEAYA Biosciences (IDYA) stocks in Canada

Learn how to easily invest in IDEAYA Biosciences stocks.

IDEAYA Biosciences is a biotechnology business based in the US. IDEAYA Biosciences stocks (IDYA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $17.26 – a decrease of 0.33% over the previous week. IDEAYA Biosciences employs 83 staff and has a trailing 12-month revenue of around $35.6 million.

How to buy shares in IDEAYA Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IDYA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

IDEAYA Biosciences stock price (NASDAQ:IDYA)

Use our graph to track the performance of IDYA stocks over time.

IDEAYA Biosciences shares at a glance

Information last updated 2022-01-25.
Latest market close$15.21
52-week range$14.63 - $28.00
50-day moving average $21.40
200-day moving average $22.06
Wall St. target price$31.78
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.12

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy IDEAYA Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

IDEAYA Biosciences price performance over time

Historical closes compared with the close of $15.21 from 2022-01-27

1 week (2022-01-18) -6.34%
1 month (2021-12-25) N/A
3 months (2021-10-29) -29.06%
6 months (2021-07-29) -35.25%
1 year (2021-01-29) -13.48%
2 years (2020-01-28) 68.07%
3 years (2019-01-25) N/A
5 years (2017-01-25) N/A

IDEAYA Biosciences financials

Revenue TTM $35.6 million
Gross profit TTM $-20,160,000
Return on assets TTM -6.63%
Return on equity TTM -14.3%
Profit margin -103.19%
Book value $8.26
Market capitalisation $632.5 million

TTM: trailing 12 months

IDEAYA Biosciences share dividends

We're not expecting IDEAYA Biosciences to pay a dividend over the next 12 months.

IDEAYA Biosciences share price volatility

Over the last 12 months, IDEAYA Biosciences's shares have ranged in value from as little as $14.6307 up to $28. A popular way to gauge a stock's volatility is its "beta".

IDYA.US volatility(beta: 1.55)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IDEAYA Biosciences's is 1.5496. This would suggest that IDEAYA Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

IDEAYA Biosciences overview

IDEAYA Biosciences, Inc. , a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients with solid tumors having MTAP deletions; PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc.

Stocks similar to IDEAYA Biosciences

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site